medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2025, Number 1

<< Back Next >>

Rev Nefrol Dial Traspl 2025; 45 (1)

Bibliometric analysis of the 250 most cited articles about Cisplatin Nephrotoxicity

Ozturk I, Uzun M

Language: English
References: 14
Page: 24-31
PDF size: 299.30 Kb.


ABSTRACT

Introduction: Cisplatin is an antineoplastic drug commonly used to treat solid tumors. Nephrotoxicity is one of the most important side effects. Our study aimed to present an objective perspective on this topic by performing a bibliometric analysis of literature articles on cisplatin nephrotoxicity. Materials and Methods: Due to analysis of the Web of Science (WoS) Core Collection database, the 250 original articles written in English about cisplatin nephrotoxicity with most citations were identified and investigated. Results: From 10,242 articles related to cisplatin nephrotoxicity, 250 original articles with the highest citation numbers were identified after exclusion criteria. These articles were published in 90 different journals. The country with the most publications and publications with the most citations about this topic was the United States of America (USA). The article with the most citations was written by Mishra et al. The most productive journal was Kidney International, while the most effective was the Journal of Clinical Investigation. Conclusion: This study is the first bibliometric analysis in the literature related to cisplatin nephrotoxicity. To date, studies have focused on the mechanisms and injuries caused by cisplatin in kidney dysfunction. The relatively low number of studies about preventing this injury is notable. Current studies that will be performed on this topic may attract researchers’ interest.


REFERENCES

  1. Pabla N, Dong Z. Cisplatin nephrotoxicity:mechanisms and renoprotective strategies. KidneyInt. 2008.73(9):994-1007. https://doi.org/10.1038/sj.ki.5002786.

  2. Cohen SM, Lippard SJ. Cisplatin: from DNA damageto cancer chemotherapy. Prog Nucleic Acid Res MolBiol. 2001(67):93-130. https://doi.org/10.1016/S0079-6603(01)67026-0.

  3. Heiger-Bernays WJ, Essigmann JM, Lippard SJ. Effectof the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNAreplication. Biochemistry. 1990. 29(36):8461-8466.

  4. Siddik ZH. Cisplatin: mode of cytotoxic actionand molecular basis of resistance. Oncogene.2003. 22(47):7265-7279. https://doi.org/10.1038/sj.onc.1206933.

  5. Florea AM, Büsselberg D. Cisplatin as an antitumordrug: cellular mechanisms of activity, drug resistance,and induced side effects. Cancers. 2011. 3(1):1351-1371. https://doi.org/10.3390/cancers3011351.

  6. Arany I, Safirstein RL. Cisplatin nephrotoxicity.Semin Nephrol. 2003. 23(5):p. 460-464. https://doi.org/10.1016/S0270-9295(03)00089-5.

  7. Pasetto LM, D’Andrea MR, Brandes AA, RossiE, Monfardini S. The development of platinumcompounds and their possible combination. CritRev Oncol/Hematol. 2006. 60(1):59-75. https://doi.org/10.1016/j.critrevonc.2006.02.003.

  8. Bajorin DF, Bosl GJ, Alcock NW, NiedzwieckiD, Gallina E, Shurgot B. Pharmacokineticsof cis-diamminedichloroplatinum (II) afteradministration in hypertonic saline. Cancer Res.1986. 46(11):5969-5972.

  9. Kumar LM, George RJ, Anisha PS. Bibliometricanalysis for medical research. Indian J PsycholMed. 2023. 45(3): p. 277-282. https://doi.org/10.1177/02537176221103617.

  10. Szomszor M, Adams J, Fry R, Gebert C, PendleburyDA, Potter RWK, et al. Interpreting bibliometric data.Frontiers Res Metrics Analytics. 2021. 5:628703.https://doi.org/10.3389/frma.2020.628703.

  11. Arruda H, Silva ER, Lessa M, Proença Jr D, BartholoR. VOSviewer and bibliometrix. JMLA. 2022.110(3):392. https://doi.org/10.5195/jmla.2022.1434

  12. Nigam M, Aschebrook-Kilfoy B, Shikanov S &Eggener S. Increasing incidence of testicular cancerin the United States and Europe between 1992 and2009. World J Urol. 2015. 33:623-631. https://doi.org/10.1007/s00345-014-1361-y.

  13. Thompson‐Harvey A, Yetukuri M, Hansen AR,Simpson MC, Boakye EA, Varvares MA, et al.Rising incidence of late‐stage head and neck cancerin the United States. Cancer. 2020. 126(5):1090-1101.https://doi.org/10.1002/cncr.32583.

  14. Sharma R, Singh VJ, Chawla PA. Advancements inthe use of platinum complexes as anticancer agents.AnticancerAgents Med Chem. 2022. 22(5):821 835.https://doi.org/10.2174/18715206216662108051507




2020     |     www.medigraphic.com